Type
miREIA – miRNA enzyme immunoassay
Applications
Whole blood
Sample Requirements
10 µl/well
Storage/Expiration
Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
25 – 0.78 amol/μl
Limit of Detection
0.26 amol/μl
Intra-assay (Within-Run)
n = 8,
CV = 4.1%
Inter-assay (Run-to-Run)
n = 5,
CV = 8.1%
Spiking Recovery
87.6%
Dilutation Linearity
96.8%
Features
- It is intended for research use only
- The total assay time is less than 2.5 hours
- The kit measures hsa-miR-486-5p isolated from human blood
- Assay format is 96 wells
- Standard is synthetic miRNA-based
- Components of the kit are provided ready to use, concentrated or dried
Research topic
Oncology
Summary
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
hsa-miR-486-5p is located on the chromosome 8, in the region which contains potential tumor-suppressor genes and is often deleted in various types of tumors.
hsa-miR-486-5p gene was first cloned from the fetal liver. Reduced miR‑486-5p expression is a frequent molecular event in human malignancies.
Deregulation of cancer-related miR-486-5p is a common event in both benign and malignant human breast tumors. miR-486-5p is one of the most downregulated miRNAs in lung tumor tissues. Its decreased level in circulation indicates lung cancer progression and metastasis. Thus, serum miR-486-5p has a great potential to serve as a marker in clinical diagnosis of lung cancers. Several studies have also shown aberrant miR-486-5p expression and its prognostic value in digestive system cancers. miR-486-5p may become a novel target in treatment of patients with gastric cancers. Other cancer types associated with deregulated miR-486-5p levels are hepatocellular carcinomas and prostate cancer.
